KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index

Target is scheduled to report its Q2 2026 financial results on August 19, 2026, with analysts forecasting EPS around $2.21-$2.25. Medium importance is assigned as upcoming earnings are significant catalysts with expected price movement between 5-10%. This event is scheduled.

Second quarter 2026 earnings release is scheduled.

Q2 2026 earnings release on August 6, 2026, with an estimated ~1% price impact, scheduled.

MetLife is scheduled to release its Q2 2026 financial results after the market closes on August 5, 2026; due to typical earnings volatility, a price impact of at least 5% is expected.

Q3 2026 earnings release scheduled, with analysts forecasting EPS of approximately $1.66. As this is a significant quarterly update, a medium impact is forecasted.

Second-quarter 2026 earnings release scheduled for July 31, 2026. Low importance is based on the expected market reaction to a standard earnings release. Analysts forecast earnings per share of approximately $3.76 estimated.

Amgen's Q2 2026 earnings release is scheduled for July 30, 2026; this routine scheduling is estimated to have a ~1% price impact, scheduled.

Q2 2026 earnings release is scheduled.

Procter & Gamble is expected to release its Q4 2026 earnings results on July 29, 2026, based on past reporting schedules. A price impact of approximately 5% is estimated based on historical earnings volatility. This is scheduled.

UPS Q2 2026 earnings release and conference call scheduled for July 28, 2026; analysts forecast EPS of approximately $1.64 on revenues of $21.6B forecasted. Significant market volatility is likely following the earnings report, so high importance is expected.

Mondelez International is scheduled to release its Q2 2026 financial results after market close on July 28, 2026; 5-10% price volatility is expected.

Sysco is expected to announce its Q4 2026 earnings results on July 28, 2026, with an EPS of approximately $1.51 as analysts forecast, scheduled. This event is estimated to have a medium market impact of at least 5% as earnings releases typically drive significant price movement.

Booz Allen Hamilton is scheduled to release its first quarter fiscal 2027 earnings results on July 24, 2026. A price impact of ≥1% is estimated as quarterly earnings typically influence stock price scheduled

Q2 2026 earnings results are scheduled to be released on July 24, 2026, before the market opens; Low importance estimated as earnings typically drive price movements exceeding 1% scheduled

Comcast is scheduled to announce its Q2 2026 financial results on July 23, 2026. Low impact expected as it is a routine schedule announcement, scheduled.

CME Group is scheduled to announce its earnings for the second quarter of 2026 before the market opens on Wednesday, July 22, 2026, which is scheduled.

Q2 2026 earnings release on July 22, 2026, which is a major catalyst for price movement justifying a medium importance estimate of >=5% impact, is scheduled.

Preferred Bank is expected to release its financial results for the second quarter of 2026, scheduled. Low impact estimated based on historical price stability during earnings releases.

Ex-dividend date on July 17, 2026, for a quarterly dividend of $1.02 per share, payable on July 31, 2026; this routine action is estimated to have a ~1% price impact and is expected.

Regions Financial Corp. Q2 2026 earnings release scheduled.

Bank OZK's Q2 2026 earnings release is scheduled. This is a recurring event with the potential for significant price impact based on results versus expectations, scheduled.

UnitedHealth Group will release its second quarter 2026 financial results on July 16, 2026, before the market opens. Market impact is estimated to be low as the actual performance is yet to be disclosed, scheduled.

Quarterly dividend of $0.63 per share, with the ex-dividend date on 2026-07-15 scheduled.

Q2 2026 earnings release scheduled. The date was announced on June 4, 2026. Estimated 5% impact based on historical volatility, scheduled.

CEO David M. Cordani is scheduled to retire, to be succeeded by current President and COO Brian Evanko, effective July 1, 2026; high importance estimated due to significant leadership transition scheduled.

Quarterly dividend ex-date of $0.33 per share on July 1, 2026, with payment scheduled for July 22, 2026. Low impact expected as dividends are typically priced in, expected.

Announcement of fiscal Q3 2026 earnings results scheduled. Expected to have neutral impact as it is a routine announcement.

Fourth quarter and full-year fiscal 2026 financial results are scheduled to be released after market close on June 30, 2026. Analysts forecast EPS of $0.11 on revenues of $10.87 billion, representing a year-over-year decline. High importance is assigned as earnings releases for major companies typically result in significant price volatility scheduled.

Quarterly dividend of $1.61 per share, ex-dividend date on June 30, 2026.

CME Group is scheduled to launch four new E-mini equity index futures contracts on June 29, 2026, pending regulatory review, which is scheduled.

Darden Restaurants will report its fiscal 2026 fourth quarter and full-year financial results before the market opens on June 25, 2026. The importance is estimated as Medium as full-year results can lead to significant price movement, which is scheduled.

Investor Day 2026 where the company is expected to outline its growth and diversification strategy, with a focus on AI across data centers, automotive, and personal computing, scheduled.

Paychex to release Q4 and full-year fiscal 2026 financial results on June 24, 2026, scheduled. Estimated 5% price impact as earnings reports typically drive moderate volatility.

Quarterly dividend ex-dividend date of $0.53 per share on 2026-06-15. Estimated Low importance as price typically adjusts by the dividend amount on the ex-date. Scheduled.

The ex-dividend date for the $0.85 per share quarterly dividend, announced on May 26, 2026, is June 15, 2026. Internal analysis estimates a low impact (~1%) as it is a routine corporate action, expected.

The ex-dividend date for a quarterly cash dividend of $2.32 per share on June 15, 2026, an increase from the previous dividend.

The U.S. Food and Drug Administration (FDA) approved KEYTRUDA in combination with WELIREG for the adjuvant treatment of adult patients with a specific type of renal cell carcinoma (ccRCC) at risk of recurrence after surgery on June 12, 2026. Internal analysis estimates a moderate positive impact (~5%) as it expands the use of a key product, expected.

Quarterly dividend with an ex-dividend date of June 12, 2026. The dividend of $1.70 per share is scheduled to be paid on July 1, 2026, scheduled. Routine dividends typically result in minimal price impact.

On June 12, 2026, CEO Mike Wirth stated that the company is continuing to look at new investment opportunities in the Middle East, citing more favorable terms.

Ex-dividend date for a quarterly cash dividend of $0.40 per share on 2026-06-12. A price impact of approximately 1% is estimated due to the standard ex-dividend price adjustment.

Ex-dividend date for a quarterly cash dividend of $0.525 per share. The dividend is payable on June 29, 2026.

The European Commission granted marketing authorization for IMDYLLTRA on June 11, 2026, for ES-SCLC treatment; this expansion into the European market is estimated to have a ~5% positive price impact, expected.

Takeda's announcement on June 11, 2026, that its TYK2 inhibitor zasocitinib was superior to Sotyktu in a Phase 3 trial, indicating future competition, is expected; 5% price impact estimated due to competitive threat.

Released its 2025 Human Rights Due Diligence and Modern Slavery Report on June 11, 2026. ESG reports typically have a minimal price impact of approximately 1%.

The Board of Directors announced a 1.8% increase in the quarterly dividend to $1.16 per share. The dividend is payable on September 1, 2026, to shareholders of record as of August 12, 2026. Low importance is assigned as modest dividend increases generally result in price impacts under 5%.

The ex-dividend date for a quarterly dividend of $0.59 per share was June 10, 2026. The dividend is payable on June 26, 2026.

At the 2026 Annual Meeting of Stockholders held on June 10, 2026, all eleven board nominees were re-elected, executive compensation was approved on an advisory basis, and the company's independent auditor was ratified. A stockholder proposal was not approved.

On June 10, 2026, RBC Capital Markets downgraded its price target on Nike stock from $70 to $50, citing a slower-than-expected revenue growth turnaround estimated.

At the 2026 Annual Meeting of Shareholders, all 12 director nominees were elected and shareholders approved the advisory 'Say on Pay' proposal. Three shareholder proposals were rejected. Low importance is assigned as routine governance outcomes typically have minimal price impact.

Reported assets under management (AUM) of $1.89 trillion as of May 31, 2026, an increase from $1.83 trillion in April, with net inflows of $3.3 billion for May. Market impact estimated at <5% due to the routine nature of monthly AUM updates, expected.

Quarterly dividend of $1.30 per share with an ex-dividend date of June 9, 2026.

Announced a multi-year expansion of its partnership with Gatik to deploy more autonomous trucks across its North American supply chain.

Regions Financial participated in the Morgan Stanley U.S. Financials Conference on June 9, 2026.

Introduced a new 26-cell electric vehicle (EV) battery monitor (BQ79826Z-Q1) on June 9, 2026, with integrated electrochemical impedance spectroscopy (EIS) to enhance battery management systems. Low importance is assigned as product launches typically result in >=1% price impact.

Announced the divestment of certain Eagle Ford shale assets to Ensign Energy on June 8, 2026, as part of portfolio rationalization following the Marathon Oil acquisition.

Merck and Gilead announced on June 8, 2026, the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study for KEYTRUDA combined with Trodelvy in non-small cell lung cancer. Internal analysis estimates a moderate negative impact (~5%) due to the failure of a late-stage trial in a major indication, expected.

Merck and Gilead announced on June 8, 2026, that two Phase 3 trials (ISLEND-1 and ISLEND-2) for their investigational once-weekly oral HIV treatment, islatravir/lenacapavir, met their primary efficacy endpoints. Internal analysis estimates a moderate positive impact (~5%) as it validates a new treatment regimen, expected.

Best Buy announced the launch of 'Meta Lab @ Best Buy' in over 50 stores on 2026-06-08. This event is estimated to have a low market impact (approx. 1%) as it is a retail partnership expansion, estimated.